New Therapy Option Approved For Use In Hiv-Infected Children
Pharmaceutical company Gilead Sciences announced the expansion of indications for the drug Biktarvi (tenofovir alafenamide, emtricitabine, bictegravir), which is now available for the treatment of HIV-1 infection not only in adults, but also in children aged 6 years and older with a body weight of at least 25 kg in the absence of any mutations associated with resistance to drugs of the integrase inhibitor class, emtricitabine or tenofovir.
It is one of the most modern drugs with an innovative treatment regimen designed to increase adherence to therapy due to its simplicity and convenience: the pill should be taken only once a day, regardless of the meal and sleep schedule.
In clinical studies in adults, the effectiveness of the drug has been demonstrated, including in patients with high viral load and low CD4 cell counts. The drug does not increase the risk of developing complications from the cardiovascular system in patients with HIV and has a favorable tolerance profile in relation to renal function, in particular, in clinical studies there were no cases of interruption of treatment due to the development of adverse events from the kidneys and urinary tract ... Also, the drug has a high barrier of resistance - in the course of clinical trials, not a single case of its development was registered.